← Leaderboards
Steven Lee Wagner
University Of California, San Diego
$8,475,404
Attributed
$10,418,408
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2011–21$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$10,418,408 · 5
VA$0 · 1
By mechanism
U01$6,532,400 · 2
R01$3,156,733 · 1
R21$419,275 · 1
R34$310,000 · 1
I01$0 · 1
Top collaborators
- Douglas R Galasko2 shared
- Robert A Rissman2 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- William C Mobley$20,695,689
- Andrew D Chisholm$11,607,483
- Valerie Anne Schmidt$1,526,659
- Hannah Kathryn Carter$5,473,840
- Christina Sigurdson$15,317,187
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseDoseNeurofibrillary TanglesProductionGamma SecretaseBrainIn VitroBaseBiochemicalLeadTransgenic MiceAmyloid Beta-ProteinAnimal ModelPreventMouse ModelChronicPropertySecretasePeptidesPlasmaAffectPathogenesisPre-Clinical
Grant awards (21)
A Single Ascending Dose / Multiple Ascending Dose Phase I study of the GSM 776890 in healthy normal subjects$3,156,733
R01 · FY2021 · AG · contact PI
A Dominantly Inherited AD network In Vitro Trial with a Gamma-Secretase Modulator$0
I01 · FY2020 · VA · contact PI
Optimization and preclinical development of soluble gamma-secretase modulators for AD$393,750
U01 · FY2019 · AG · contact PI
A Dominantly Inherited AD network In Vitro Trial with a Gamma-Secretase Modulator$0
I01 · FY2019 · VA · contact PI
Optimization and preclinical development of soluble gamma-secretase modulators for AD$1,497,030
U01 · FY2018 · AG · contact PI
Optimization and preclinical development of soluble gamma-secretase modulators for AD$198,079
U01 · FY2018 · AG · contact PI
A Dominantly Inherited AD network In Vitro Trial with a Gamma-Secretase Modulator$0
I01 · FY2018 · VA · contact PI
Optimization and preclinical development of soluble gamma-secretase modulators for AD$1,513,937
U01 · FY2017 · AG · contact PI
A Dominantly Inherited AD network In Vitro Trial with a Gamma-Secretase Modulator$0
I01 · FY2017 · VA · contact PI
Optimization and preclinical development of soluble gamma-secretase modulators for AD$1,514,460
U01 · FY2016 · AG · contact PI
Polytherapy for AD: Combining Gamma-secretase Modulation and CRFR1 Antagonism$225,525
R21 · FY2015 · AG · contact PI
Optimization of Soluble Gamma-secretase Modulators for the Treatment of Alzheimer$52,995
U01 · FY2015 · NS · contact PI
Translational Center for Alzheimer's Disease Target and Drug Discovery$310,000
R34 · FY2014 · AG
Optimization of Soluble Gamma-secretase Modulators for the Treatment of Alzheimer$300,863
U01 · FY2014 · NS · contact PI
Polytherapy for AD: Combining Gamma-secretase Modulation and CRFR1 Antagonism$193,750
R21 · FY2014 · AG · contact PI
Optimization of Soluble Gamma-secretase Modulators for the Treatment of Alzheimer$331,871
U01 · FY2013 · NS · contact PI
Optimization of Soluble Gamma-secretase Modulators for the Treatment of Alzheimer$74,811
U01 · FY2013 · NS · contact PI
Optimization of Soluble Gamma-secretase Modulators for the Treatment of Alzheimer$255,273
U01 · FY2012 · NS · contact PI
Optimization of Soluble Gamma-secretase Modulators for the Treatment of Alzheimer$77,245
U01 · FY2012 · NS · contact PI
Optimization of Soluble Gamma-secretase Modulators for the Treatment of Alzheimer$77,046
U01 · FY2012 · NS · contact PI
Optimization of Soluble Gamma-secretase Modulators for the Treatment of Alzheimer$245,040
U01 · FY2011 · NS · contact PI